ArticleJournal of clinical and experimental hematopathology : JCEH2026
Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma.
Akihiro Kawatsuki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.